Gemcitabine Treatment in Pretreated Cutaneous T-Cell Lymphoma: Experience in 44 Patients

• DOI: 10.1200/jco.2000.18.13.2603
• Publication Date: 2017-02-24T09:08:21Z
• Authors: Pier Luigi Zinzani; Gianandrea Baliva; Massimo Magagnoli; Maurizio Bendandi; Gino Modugno; Filippo Gherlinzoni; Giulio Fraternali...; Stefano Ascani; Romeo Simoni; Stefano A. Pileri; Sante Tura
• Keywords: Refractory (planetary science); Cutaneous T-cell lymphoma; T-Cell Lymphoma

To evaluate the efficacy and toxicity of gemcitabine, a novel pyrimidine antimetabolite with low-toxicity profile activity in several solid tumors, patients relapsed or refractory cutaneous T-cell lymphomas.Between May 1997 February 1999, 44 previously treated mycosis fungoides (MF; n = 30) peripheral lymphoma unspecified (PTCLU) exclusive skin involvement (n 14) were enrolled onto two-institution, phase II trial gemcitabine. This drug was given on days 1, 8, 15 28-day schedule at dose 1,200 mg/m(2) intravenously over 30 minutes for total three courses.Of patients, five (11. 5%) achieved complete responses (CRs), 26 (59%) partial (PRs), remaining 13 showed no benefit from treatment. Two CRs histologically confirmed. The CR PR rates same MF those PTCLU, respectively. No difference terms overall response rate observed between patients. median durations months (range, 6 to 22 months) 10 2 months), Treatment well tolerated; hematologic mild, nausea/vomiting organ recorded.The results present study show gemcitabine as single agent pretreated lymphoma. Further studies that use alone combination other drugs earlier stages disease are needed.